Monday, 18 Nov 2019

You are here

2018 Swedish Guidelines for Giant Cell Arteritis Treatment

The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab. 

Beyond pharmacological treatment, they address the use of temporal artery biopsy (TAB) and other imaging techniques (magnetic resonance imaging and positron emission tomography/computed tomography) for the evaluation of large-vessel involvement.

Steroids (oral, or intravenous in cases with ischaemic complications) remain the first line for GCA, and tocilizumab (TCZ) is only recommended for patients with relapsing disease who meet one of five criteria for active disease. Current evidence suggests that tocilizumab treatment for > 1 year cannot be recommended.

Exerpts from this comprehensive guideline are provided below.

New Proposed GCA Classification  

Original criteria, ACR 1990Hunder GGBloch DAMichel BAStevens MBArend WPCalabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:11228.[Crossref][PubMed][Web of Science ®], [Google ScholaProposal for new, extended criteria*Dejaco CDuftner CButtgereit FMatteson ELDasgupta BThe spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford) 2017;56:50615.[PubMed][Web of Science ®], [Google Schola
Age at onset of disease ≥ 50 yearsAge at onset of disease ≥ 50 years
New headache or new type of localized pain in the head, visual symptoms, loss of sight, PMR, constitutional symptoms, and/or jaw claudicationAny of the following: new headache of new type and localization, chewing, and/or jaw claudication
Tenderness at palpation or low pulse at the temporal arteryTenderness at palpation or low pulse at the temporal artery and/or extracranial arteries
ESR ≥ 50 mm/hESR ≥ 50 mm/h and/or CRP ≥ 10 mg/L
Positive temporal artery biopsy (granulomatous arteritis or arteritis with mononuclear cells, giant cells)Positive temporal artery biopsy (granulomatous arteritis or arteritis with mononuclear cells, giant cells) and/or imaging diagnostics using ultrasonography findings, MRI, and/or FDG-PET.

*These criteria are based on opinions and should not be used in clinical practice or in clinical studies. A patient has GCA if three out of five criteria are met, provided the biopsy is positive and/or the imaging diagnostics results are compatible with a GCA diagnosis.

Recommendations for Glucocorticoid Use

  1. Glucocorticosteroids remain first line for the treatment of GCA.
  2. It is vital not to delay treatment, for example while waiting for a temporal artery biopsy.
  3. The recommended initial dose of prednisolone is 40–60 mg for 4 weeks, thereafter gradually tapered.
  4. If vision is impaired or there are other signs of serious vascular involvement, intravenous methylprednisolone 1000 mg once daily for 3 days may be considered, followed by oral treatment as above.
  5. The rationale for treating GCA with tocilizumab is primarily its glucocorticoid-sparing effect over time.

Suggested Schedule for Reducing Glucocorticosteroid Treatment for GCA

  1. 40–60 mg prednisolone/day for approximately 4 weeks (until ESR and CRP have been normalized, and signs and symptoms have improved
  2. Thereafter, reduction of the dose by 10 mg every other week to 20 mg daily
  3. Thereafter, reductions of 2.5 mg with 2–4 week intervals to 10 mg daily
  4. If there are no signs of relapse, the dose may be reduced by 1 mg every month or every other month.
  5. Follow-up and treatment modification After every dose reduction, the patient’s ESR and CRP are checked and the return of signs and symptoms is also checked.
  6. If signs and symptoms of active disease return, the dose of prednisolone should be increased to the latest effective dose.

Recommendations for Tocilizumab Use

  1. Tocilizumab is recommended as a supplement to prednisolone treatment in patients with recurrent or active illness during glucocorticoid treatment, providing the criteria set in the guidelines are met.
  2. In cases of newly diagnosed GCA, tocilizumab may be considered when there is a great risk of future side effects of glucocorticoids, and pronounced clinical and laboratory signs of vascular inflammation.
  3. Treatment with tocilizumab should be discontinued after 1 year. (Longer periods of treatment cannot be recommended with our present state of knowledge)
  4. If inflammation persists after 1 year of treatment with tocilizumab, an individual assessment must be made by the treating physician.

Criteria for Addition of Tocilizumab

  1. Relapse during glucocorticoid treatment or relapse after the completion of treatment with glucocorticoids
  2. Large vessel arteritis that has at some point been verified with biopsy or with imaging of large vessels (MRI, PET-CT, or CT angiography)
  3. Clinically active giant cell arteritis
  4. Elevated CRP and ESR
  5. Obvious side effects of glucocorticoid treatment or great risk of such side effects from future treatment with glucocorticoids

These draft guidelines were written by a small group of experts, based on current standards in Sweden, and with broad discussion within the rheumatology community. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.